0001209191-23-057387.txt : 20231205 0001209191-23-057387.hdr.sgml : 20231205 20231205160941 ACCESSION NUMBER: 0001209191-23-057387 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231201 FILED AS OF DATE: 20231205 DATE AS OF CHANGE: 20231205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Allan Jonathan CENTRAL INDEX KEY: 0001966716 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38938 FILM NUMBER: 231466659 MAIL ADDRESS: STREET 1: C/O STOKE THERAPEUTICS, INC. STREET 2: 45 WIGGINS AVENUE CITY: BEDFORD STATE: MA ZIP: 01730 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Stoke Therapeutics, Inc. CENTRAL INDEX KEY: 0001623526 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 471144582 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 45 WIGGINS AVENUE CITY: BEDFORD STATE: MA ZIP: 01730 BUSINESS PHONE: 781-430-8200 MAIL ADDRESS: STREET 1: 45 WIGGINS AVENUE CITY: BEDFORD STATE: MA ZIP: 01730 FORMER COMPANY: FORMER CONFORMED NAME: ASOthera Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20141028 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-12-01 0 0001623526 Stoke Therapeutics, Inc. STOK 0001966716 Allan Jonathan C/O STOKE THERAPEUTICS, INC. 45 WIGGINS AVENUE BEDFORD MA 01730 0 1 0 0 General Counsel & Corp Sec 0 Employee Stock Option (Right to Buy) 59.84 2023-12-01 4 D 0 65000 D 2031-02-15 Common Stock 65000 0 D Employee Stock Option (Right to Buy) 20.34 2023-12-01 4 D 0 121100 D 2032-03-14 Common Stock 121100 0 D Restricted Stock Unit (RSU) 2023-12-01 4 A 0 46284 0.00 A 2025-12-01 Common Stock 46284 46284 D The canceled option vested as to 1/4th of the total award on February 16, 2022, and provided for 1/48th of the total award to vest monthly thereafter, subject to the reporting person's continued service to the Issuer through each vesting date. On December 1, 2023, the Issuer cancelled, pursuant to the Issuer's option exchange program, options to purchase 65,000 shares of Common Stock of the Issuer and in exchange issued to the reporting person 8,441 restricted stock units. The canceled option vested as to 1/48th of the total award on April 15, 2022 and provided for 1/48th of the total award to vest monthly thereafter, subject to the reporting person's continued service to the Issuer through each vesting date. On December 1, 2023, the Issuer cancelled, pursuant to the Issuer's option exchange program, options to purchase 121,100 shares of Common Stock of the Issuer and in exchange issued to the reporting person 37,843 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. 33,927 restricted stock units will vest on December 1, 2024 and 12,357 will vest on December 1, 2025, subject to the reporting person's continued service to the Issuer on each such date. /s/ Stephen Tulipano, Attorney-in-Fact 2023-12-05